Hu YF, et al. – In this prospective cohort study including 395 individuals with atrial fibrillation (AF) receiving non-vitamin K antagonist oral anticoagulants (NOACs) over a mean follow-up of 2.8 years, researchers determine the associations of bleeding events with new-onset cancers. They evaluated 18 study participants with new-onset cancers that were diagnosed 584 ± 372 days after the initiation of NOACs. They noted that, in the multivariate logistic regression, an independent correlation was evident between bleeding events that preceded the diagnosis of new-onset cancers and new-onset cancers. Either a significant period of drug interruption for at least 2 months or NOACs discontinuation was observed in more than half of the patients (61%) with new-onset cancers. Overall, thorough surveillance to detect early cancers was recommended in the presence of bleeding in patients with AF receiving NOACs as this could be a warning sign of new-onset cancers.